CO5640102A2 - Composiciones farmaceuticas de agonista parcial de 5ht4 - Google Patents
Composiciones farmaceuticas de agonista parcial de 5ht4Info
- Publication number
- CO5640102A2 CO5640102A2 CO04067463A CO04067463A CO5640102A2 CO 5640102 A2 CO5640102 A2 CO 5640102A2 CO 04067463 A CO04067463 A CO 04067463A CO 04067463 A CO04067463 A CO 04067463A CO 5640102 A2 CO5640102 A2 CO 5640102A2
- Authority
- CO
- Colombia
- Prior art keywords
- composition according
- partial agonist
- weight
- pharmaceutical compositions
- percent
- Prior art date
Links
- 239000004031 partial agonist Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 2
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical group C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 abstract 2
- 229960002876 tegaserod Drugs 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01403339A EP1321142A1 (en) | 2001-12-21 | 2001-12-21 | Solid pharmaceutical composition for oral administration of Tegaserod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5640102A2 true CO5640102A2 (es) | 2006-05-31 |
Family
ID=8183045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04067463A CO5640102A2 (es) | 2001-12-21 | 2004-07-15 | Composiciones farmaceuticas de agonista parcial de 5ht4 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20050106236A1 (enExample) |
| EP (2) | EP1321142A1 (enExample) |
| JP (1) | JP4718776B2 (enExample) |
| KR (1) | KR100980144B1 (enExample) |
| CN (1) | CN100464749C (enExample) |
| AR (1) | AR037937A1 (enExample) |
| AT (1) | ATE320807T1 (enExample) |
| AU (1) | AU2002361198B2 (enExample) |
| BR (1) | BR0215148A (enExample) |
| CA (1) | CA2470668C (enExample) |
| CO (1) | CO5640102A2 (enExample) |
| CY (1) | CY1105559T1 (enExample) |
| DE (1) | DE60210139T2 (enExample) |
| DK (1) | DK1458377T3 (enExample) |
| EC (1) | ECSP105163A (enExample) |
| EG (1) | EG24194A (enExample) |
| ES (1) | ES2258171T3 (enExample) |
| HU (1) | HU226589B1 (enExample) |
| IL (2) | IL162451A0 (enExample) |
| MX (1) | MXPA04006157A (enExample) |
| MY (1) | MY139546A (enExample) |
| NO (1) | NO20042779L (enExample) |
| NZ (1) | NZ533585A (enExample) |
| PE (1) | PE20030872A1 (enExample) |
| PL (1) | PL369509A1 (enExample) |
| PT (1) | PT1458377E (enExample) |
| RU (1) | RU2322978C2 (enExample) |
| SI (1) | SI1458377T1 (enExample) |
| TW (1) | TWI260221B (enExample) |
| WO (1) | WO2003053432A1 (enExample) |
| ZA (1) | ZA200404467B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID28510A (id) * | 1998-08-21 | 2001-05-31 | Novartis Ag | Formulasi oral yang baru untuk agonis atau antagonis 5-ht4 |
| BR122018074353B8 (pt) | 2003-01-28 | 2023-05-02 | Ironwood Pharmaceuticals Inc | composição farmacêutica, polipeptídeo e métodos para a produção dos mesmos |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004085393A1 (en) * | 2003-03-25 | 2004-10-07 | Hetero Drugs Limited | Novel crystalline forms of tegaserod maleate |
| US20070065801A1 (en) * | 2003-05-21 | 2007-03-22 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4) |
| PE20050253A1 (es) * | 2003-07-24 | 2005-06-03 | Novartis Ag | Modificaciones estables de maleato de hidrogeno de tegaserod |
| AR045637A1 (es) | 2003-09-12 | 2005-11-02 | Amgen Inc | Formulacion de disolucion rapida de un compuesto activo frente a los receptores de calcio |
| EP1594493A2 (en) * | 2003-12-16 | 2005-11-16 | Teva Pharmaceutical Industries Ltd. | Polymorphic forms of tegaserod base and salts thereof |
| CZ298399B6 (cs) * | 2005-05-02 | 2007-09-19 | Zentiva, A. S. | Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu) |
| US20070259052A1 (en) | 2006-05-05 | 2007-11-08 | Shire International Licensing B.V. | Assay for lanthanum hydroxycarbonate |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| CN103819403B (zh) | 2008-12-31 | 2017-01-04 | 阿德利克斯公司 | 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法 |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| RU2015107019A (ru) | 2012-08-21 | 2016-10-10 | Эрделикс Инк. | Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| CN105392483B (zh) | 2013-04-12 | 2019-03-15 | 阿德利克斯公司 | 用于抑制磷酸盐转运的nhe3结合化合物和方法 |
| CN104922083B (zh) * | 2015-04-15 | 2017-12-22 | 湖南尔康湘药制药有限公司 | 磺胺嘧啶片及其制备方法 |
| WO2017064538A1 (en) * | 2015-10-16 | 2017-04-20 | Nobel Ilac Sanayii Ve Ticaret A.S. | Pharmaceutical compositions of nilotinib hydrochloride |
| EA201991676A1 (ru) | 2017-01-09 | 2020-01-30 | Арделикс, Инк. | Ингибиторы nhe-опосредованного антипорта |
| KR20240090875A (ko) | 2017-01-09 | 2024-06-21 | 알데릭스, 인코포레이티드 | 위장관 장애를 치료하는 데 유용한 화합물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0820586A (ja) * | 1994-07-05 | 1996-01-23 | Sanwa Kagaku Kenkyusho Co Ltd | １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途 |
| IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
| JPH09194374A (ja) * | 1995-11-14 | 1997-07-29 | Taisho Pharmaceut Co Ltd | 消化器疾患治療剤 |
| DE69713948D1 (de) * | 1996-04-23 | 2002-08-22 | Janssen Pharmaceutica Nv | Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid |
| US5739151A (en) * | 1996-07-19 | 1998-04-14 | Sepracor Inc. | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride |
| ID28510A (id) * | 1998-08-21 | 2001-05-31 | Novartis Ag | Formulasi oral yang baru untuk agonis atau antagonis 5-ht4 |
| US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| AU3574500A (en) * | 1999-03-25 | 2000-10-16 | Yuhan Corporation | Rapidly disintegrable tablet for oral administration |
| ATE399554T1 (de) * | 1999-08-03 | 2008-07-15 | Lilly Icos Llc | Pharmazeutische zusammensetzung enthaltend tadalafil |
-
2001
- 2001-12-21 EP EP01403339A patent/EP1321142A1/en not_active Withdrawn
-
2002
- 2002-12-17 EG EG2002121358A patent/EG24194A/xx active
- 2002-12-19 TW TW091136675A patent/TWI260221B/zh not_active IP Right Cessation
- 2002-12-19 AR ARP020105024A patent/AR037937A1/es not_active Application Discontinuation
- 2002-12-20 JP JP2003554189A patent/JP4718776B2/ja not_active Expired - Fee Related
- 2002-12-20 IL IL16245102A patent/IL162451A0/xx active IP Right Grant
- 2002-12-20 PT PT02796711T patent/PT1458377E/pt unknown
- 2002-12-20 SI SI200230334T patent/SI1458377T1/sl unknown
- 2002-12-20 MY MYPI20024825A patent/MY139546A/en unknown
- 2002-12-20 EP EP02796711A patent/EP1458377B1/en not_active Expired - Lifetime
- 2002-12-20 CN CNB028255321A patent/CN100464749C/zh not_active Expired - Fee Related
- 2002-12-20 PL PL02369509A patent/PL369509A1/xx not_active Application Discontinuation
- 2002-12-20 MX MXPA04006157A patent/MXPA04006157A/es active IP Right Grant
- 2002-12-20 AT AT02796711T patent/ATE320807T1/de active
- 2002-12-20 HU HU0402492A patent/HU226589B1/hu not_active IP Right Cessation
- 2002-12-20 WO PCT/EP2002/014674 patent/WO2003053432A1/en not_active Ceased
- 2002-12-20 KR KR1020047009594A patent/KR100980144B1/ko not_active Expired - Fee Related
- 2002-12-20 AU AU2002361198A patent/AU2002361198B2/en not_active Ceased
- 2002-12-20 DE DE60210139T patent/DE60210139T2/de not_active Expired - Lifetime
- 2002-12-20 ES ES02796711T patent/ES2258171T3/es not_active Expired - Lifetime
- 2002-12-20 BR BR0215148-0A patent/BR0215148A/pt not_active IP Right Cessation
- 2002-12-20 NZ NZ533585A patent/NZ533585A/en not_active IP Right Cessation
- 2002-12-20 CA CA2470668A patent/CA2470668C/en not_active Expired - Fee Related
- 2002-12-20 US US10/499,721 patent/US20050106236A1/en not_active Abandoned
- 2002-12-20 RU RU2004122631/15A patent/RU2322978C2/ru not_active IP Right Cessation
- 2002-12-20 DK DK02796711T patent/DK1458377T3/da active
-
2003
- 2003-01-06 PE PE2003000004A patent/PE20030872A1/es not_active Application Discontinuation
-
2004
- 2004-06-07 ZA ZA200404467A patent/ZA200404467B/en unknown
- 2004-06-10 IL IL162451A patent/IL162451A/en not_active IP Right Cessation
- 2004-07-01 NO NO20042779A patent/NO20042779L/no not_active Application Discontinuation
- 2004-07-15 CO CO04067463A patent/CO5640102A2/es not_active Application Discontinuation
-
2006
- 2006-05-04 CY CY20061100579T patent/CY1105559T1/el unknown
-
2008
- 2008-10-07 US US12/287,232 patent/US20090104263A1/en not_active Abandoned
-
2010
- 2010-06-16 EC EC2010005163A patent/ECSP105163A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP105163A (es) | Composiciones farmaceuticas de agonista parcial de 5ht4 | |
| BR0316532A (pt) | Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base | |
| HRP20090381T1 (en) | Compositions comprising drospirenone molecularly dispersed | |
| SE0302760D0 (sv) | New compounds | |
| PA8586401A1 (es) | 4-piperazinilbencenosulfonilindoles y uso de los mismos | |
| EA200701357A1 (ru) | Композиции и способы применения модулятора рецептора 5ht | |
| MXPA04000456A (es) | Analogos de prostaglandina como agonistas del receptor ep4. | |
| CO5590918A2 (es) | Formulaciones | |
| CY1113395T1 (el) | Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη | |
| EA200700566A1 (ru) | Фармацевтические композиции, включающие леветирацетам, и способы их получения | |
| CA2505964A1 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
| DK1856090T3 (da) | Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser | |
| CO5390076A1 (es) | Composiciones farmaceuticas | |
| TW200517106A (en) | Sustained release pharmaceutical compositions | |
| EA200400357A1 (ru) | Дезинтегрирующиеся в ротовой полости композиции валдекоксиба | |
| BRPI0417810B8 (pt) | arilpirazóis substituídos como agentes parasiticidas, composição veterinária e uso dos mesmos | |
| GB2421241A (en) | Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof | |
| BRPI0413676A (pt) | composto, e, composição farmacêutica | |
| MX2008001606A (es) | Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico. | |
| EA200401455A1 (ru) | Производные бензоксазина в качестве модуляторов 5-htи их применение | |
| NO20040589L (no) | Arylsulfonylderivater med 5-HT6 reseptor affinitet. | |
| PA8605101A1 (es) | 4-(aminometil)-piperidin benzamidas como antagonista de 5ht4 | |
| EA200400848A1 (ru) | Производные триазолохинолина, применимые в качестве лигандов аденозиновых рецепторов | |
| TN2010000129A1 (fr) | Nouvelles compositions a base de taxoides | |
| EA200201149A1 (ru) | Фармацевтические композиции и способы для предотвращения рецидива мигрени |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |